百亿市值药企中国医药原董事长高渝文离职四年后被查，公司至少有11人被查

Group 1 - The core issue within China National Pharmaceutical Group has been ongoing anti-corruption efforts, with multiple executives being investigated for serious violations of discipline and law [1][2][5] - As of December 26, 2025, the company had a market capitalization of 15.662 billion yuan [1][4] - The company has seen a significant turnover in its leadership, with at least 11 executives or former executives under investigation since 2024 [2][5] Group 2 - In 2024, the company reported a revenue of 34.148 billion yuan, a year-on-year decrease of 12.04%, and a net profit attributable to shareholders of 0.535 billion yuan, down 48.91% [3][6] - For the first half of 2025, the company achieved a revenue of 17.076 billion yuan, a decline of 6.71%, and a net profit of 0.294 billion yuan, down 16.19% [3][6] - By the third quarter of 2025, the net profit attributable to shareholders was 0.477 billion yuan, reflecting a year-on-year decrease of 4.64% [7]